Maximum On-Label Dose of OnabotulinumtoxinA (Botox)
The FDA-approved maximum cumulative dose of onabotulinumtoxinA is 400 units per treatment session across all indications, with a minimum interval of 3 months between treatment sessions 1.
Indication-Specific Maximum Doses
The maximum dose varies by approved indication:
Neurologic Indications
- Chronic Migraine: 155 units per session (fixed-site protocol across 31 injection sites)
- Cervical Dystonia: 200-300 units per session (individualized based on muscle involvement)
- Upper Limb Spasticity: 400 units maximum per session
- Lower Limb Spasticity: 400 units maximum per session
- Blepharospasm: Typically 30-50 units per eye per session
Urologic Indications
- Overactive Bladder (OAB): 100 units per session
- Neurogenic Detrusor Overactivity (NDO): 200 units per session
1 explicitly states that "the total dose of onabotulinumtoxinA should not exceed 360 U in a 3-month period for all indications, including those outside the urinary tract (i.e., cosmetic, ophthalmologic, etc.)," though this has been updated to 400 units in current FDA labeling.
Critical Safety Considerations
When treating multiple body regions simultaneously, the cumulative dose across ALL indications must not exceed 400 units per session 1. This is particularly important for patients receiving treatment for multiple conditions (e.g., spasticity plus bladder dysfunction).
Minimum Interval Between Treatments
- At least 12 weeks (3 months) must elapse between treatment sessions to avoid exceeding safe cumulative dosing 1
- Typical duration of effect is 4-10 months for most indications 1
Evidence for Higher Doses (Off-Label)
While the FDA maximum is 400 units, emerging evidence suggests higher doses may be safe in select patients:
- 2 demonstrated that doses >400 units (mean not specified) were well-tolerated in 68 patients with dystonia and spasticity, with >70% reporting "very much improved" or "much improved" outcomes and no serious adverse events
- 3 confirmed that 400 units in upper limb spasticity was safe and effective, with no new safety concerns
- 4 reported no life-threatening adverse events in patients receiving cumulative doses >360 units (up to 1900 units) within 3 months for multiple indications, though this was a small cohort (n=13)
- 5 from Japan (2025) reported safe dose escalation to 600 units for post-stroke spasticity with no adverse events in 24 patients
However, these higher doses remain off-label in most countries and should only be considered by experienced practitioners in carefully selected patients.
Common Pitfalls to Avoid
Dose Tracking Errors: 6 found that 50% of patients receiving injections from multiple specialists exceeded maximum recommended doses, with significant discordance between pharmacy records (46.9%) and nursing documentation (54.3%). Maintain careful documentation and communicate across specialties.
Underdosing: 7 demonstrates that treating below approved doses results in shorter duration, inferior response rates, and lower patient satisfaction without reducing adverse event risk. Avoid going below licensed doses unless there is clear clinical rationale.
Cosmetic vs. Therapeutic Confusion: The evidence provided includes cosmetic product information 8 that is not relevant to therapeutic Botox dosing. These are different products with different formulations.
Practical Algorithm for Dose Selection
For single indication:
- Use the indication-specific maximum dose as outlined above
- Do not exceed 400 units per session
For multiple indications:
- Calculate cumulative dose across all treatment sites
- Prioritize the most functionally limiting condition
- Ensure total dose ≤400 units
- Example: Patient with upper limb spasticity (300 units) + OAB (100 units) = 400 units total ✓
For repeat treatments: